Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
60.69
-0.91 (-1.48%)
At close: Apr 28, 2026, 4:00 PM EDT
60.70
+0.01 (0.02%)
After-hours: Apr 28, 2026, 4:50 PM EDT
Cytokinetics Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Cytokinetics stock have an average target of 89.26, with a low estimate of 56 and a high estimate of 136. The average target predicts an increase of 47.08% from the current stock price of 60.69.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock from 19 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 7 | 7 | 7 |
| Buy | 8 | 8 | 8 | 9 | 9 | 10 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 16 | 18 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Initiates $95 | Buy | Initiates | $95 | +56.53% | Apr 10, 2026 |
| Barclays | Barclays | Buy Maintains $87 → $95 | Buy | Maintains | $87 → $95 | +56.53% | Apr 6, 2026 |
| Mizuho | Mizuho | Buy Maintains $84 → $100 | Buy | Maintains | $84 → $100 | +64.77% | Mar 18, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $74 → $75 | Buy | Maintains | $74 → $75 | +23.58% | Mar 17, 2026 |
| UBS | UBS | Hold Maintains $61 → $69 | Hold | Maintains | $61 → $69 | +13.69% | Mar 6, 2026 |
Financial Forecast
Revenue This Year
94.53M
from 88.04M
Increased by 7.37%
Revenue Next Year
387.73M
from 94.53M
Increased by 310.19%
EPS This Year
-6.60
from -6.54
EPS Next Year
-4.84
from -6.60
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 191.5M | 527.7M | ||||||
| Avg | 94.5M | 387.7M | ||||||
| Low | 58.8M | 308.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 117.5% | 458.3% | ||||||
| Avg | 7.4% | 310.2% | ||||||
| Low | -33.2% | 226.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -5.96 | -3.43 | ||||||
| Avg | -6.60 | -4.84 | ||||||
| Low | -7.09 | -5.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.